verapamil has been researched along with Long QT Syndrome in 34 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the cellular and ionic mechanism for QT prolongation and subsequent Torsade de Pointes (TdP) and the effect of verapamil under conditions mimicking KCNQ1 (I(Ks) gene) defect linked to acquired long QT syndrome (LQTS)." | 7.73 | Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. ( Aiba, T; Ding, WG; Horie, M; Inagaki, M; Matsuura, H; Miyoshi, S; Noda, T; Shimizu, W; Sunagawa, K; Toyoda, F; Zankov, DP, 2005) |
| "This study used monophasic action potentials to investigate the effects of verapamil and propranolol on epinephrine-induced repolarization abnormalities in congenital long QT syndrome." | 7.69 | Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. ( Aihara, N; Arakaki, Y; Kamakura, S; Kamiya, T; Kawade, M; Kurita, T; Ohe, T; Shimizu, W; Shimomura, K, 1995) |
| "The emergency physician diagnosed a cardiac arrest." | 5.30 | [Torsade de pointes tachycardia during administration of quinidine and verapamil in atrial fibrillation]. ( Karch, M; Plewan, A; Schmidt, G; Schmitt, C; Schömig, A, 1997) |
| "We examined the cellular and ionic mechanism for QT prolongation and subsequent Torsade de Pointes (TdP) and the effect of verapamil under conditions mimicking KCNQ1 (I(Ks) gene) defect linked to acquired long QT syndrome (LQTS)." | 3.73 | Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. ( Aiba, T; Ding, WG; Horie, M; Inagaki, M; Matsuura, H; Miyoshi, S; Noda, T; Shimizu, W; Sunagawa, K; Toyoda, F; Zankov, DP, 2005) |
| "This study used monophasic action potentials to investigate the effects of verapamil and propranolol on epinephrine-induced repolarization abnormalities in congenital long QT syndrome." | 3.69 | Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. ( Aihara, N; Arakaki, Y; Kamakura, S; Kamiya, T; Kawade, M; Kurita, T; Ohe, T; Shimizu, W; Shimomura, K, 1995) |
| "Verapamil treatment was successful in reducing defibrillator discharge frequency of the KCNQ1/TRPM4 dual mutation patient." | 1.72 | In Vitro Drug Screening Using iPSC-Derived Cardiomyocytes of a Long QT-Syndrome Patient Carrying KCNQ1 & TRPM4 Dual Mutation: An Experimental Personalized Treatment. ( Guo, Y; Han, Y; Li, Y; Liang, X; Lu, Y; Sang, W; Tang, B; Wang, F; Wang, L; Xiaokereti, J; Xing, Q; Zhang, J; Zhang, L; Zhou, X; Zukela, T, 2022) |
| " Incidents of adverse cardiac drug reactions are more common in patients with preexisting heart disease than the general population." | 1.39 | Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. ( Bers, DM; Diecke, S; Gong, T; Knowles, JW; Lan, F; Lee, AS; Liang, P; Nguyen, PK; Robbins, RC; Sallam, K; Sanchez-Freire, V; Wang, PJ; Wang, Y; Wu, JC, 2013) |
| "Verapamil treatment augmented prolongation of MAPD( 90) caused by dofetilide or domperidone (P < ." | 1.35 | Gender-related differences in drug-induced prolongation of cardiac repolarization in prepubertal guinea pigs. ( Hreiche, R; Morissette, P; Turgeon, J; Zakrzewski-Jakubiak, H, 2009) |
| "No polymorphic ventricular tachycardias were induced under this condition." | 1.34 | Effect of calcium-channel antagonist on repolarization heterogeneity of ventricular myocardium in an in vitro rabbit model of long QT syndrome. ( Li, B; Ma, Y; Pu, J; Quan, X; Zhang, C; Zhao, G, 2007) |
| "The emergency physician diagnosed a cardiac arrest." | 1.30 | [Torsade de pointes tachycardia during administration of quinidine and verapamil in atrial fibrillation]. ( Karch, M; Plewan, A; Schmidt, G; Schmitt, C; Schömig, A, 1997) |
| "Torsade de pointes (TdP) syncopal episodes were almost invariably precipitated by emotional stress or menstruation in a 17-year-old girl." | 1.28 | Role of early afterdepolarization in familial long QTU syndrome and torsade de pointes. ( Liu, WY; Zheng, LR; Zhou, JT, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.88) | 18.7374 |
| 1990's | 7 (20.59) | 18.2507 |
| 2000's | 14 (41.18) | 29.6817 |
| 2010's | 8 (23.53) | 24.3611 |
| 2020's | 3 (8.82) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A | 1 |
| Poluzzi, E | 1 |
| De Ponti, F | 1 |
| Recanatini, M | 1 |
| Nogawa, H | 1 |
| Muraki, Y | 1 |
| Kawai, T | 1 |
| Kuninishi, Y | 1 |
| Wang, F | 1 |
| Han, Y | 1 |
| Sang, W | 1 |
| Wang, L | 2 |
| Liang, X | 1 |
| Xing, Q | 2 |
| Guo, Y | 1 |
| Zhang, J | 1 |
| Zhang, L | 2 |
| Zukela, T | 1 |
| Xiaokereti, J | 1 |
| Lu, Y | 1 |
| Zhou, X | 1 |
| Tang, B | 1 |
| Li, Y | 1 |
| Zhao, Y | 1 |
| Feng, M | 1 |
| Shang, LX | 1 |
| Sun, HX | 1 |
| Zhou, XH | 1 |
| Lu, YM | 1 |
| Li, YD | 1 |
| Tang, BP | 1 |
| Bergenholm, L | 1 |
| Parkinson, J | 1 |
| Mettetal, J | 1 |
| Evans, ND | 1 |
| Chappell, MJ | 1 |
| Collins, T | 1 |
| Webster, G | 1 |
| Schoppen, ZJ | 1 |
| George, AL | 1 |
| Liang, P | 1 |
| Lan, F | 1 |
| Lee, AS | 1 |
| Gong, T | 1 |
| Sanchez-Freire, V | 1 |
| Wang, Y | 1 |
| Diecke, S | 1 |
| Sallam, K | 1 |
| Knowles, JW | 1 |
| Wang, PJ | 1 |
| Nguyen, PK | 1 |
| Bers, DM | 1 |
| Robbins, RC | 1 |
| Wu, JC | 1 |
| Sakata, S | 1 |
| Kurata, Y | 1 |
| Li, P | 1 |
| Notsu, T | 1 |
| Morikawa, K | 1 |
| Miake, J | 1 |
| Higaki, K | 1 |
| Yamamoto, Y | 1 |
| Yoshida, A | 1 |
| Shirayoshi, Y | 1 |
| Yamamoto, K | 1 |
| Horie, M | 2 |
| Ninomiya, H | 1 |
| Kanzaki, S | 1 |
| Hisatome, I | 1 |
| Vicente, J | 2 |
| Johannesen, L | 2 |
| Mason, JW | 2 |
| Crumb, WJ | 1 |
| Pueyo, E | 2 |
| Stockbridge, N | 1 |
| Strauss, DG | 2 |
| Hosseini, M | 1 |
| Sager, PT | 1 |
| Sakaguchi, Y | 1 |
| Takahara, A | 1 |
| Nakamura, Y | 1 |
| Akie, Y | 1 |
| Sugiyama, A | 1 |
| Hreiche, R | 2 |
| Morissette, P | 2 |
| Zakrzewski-Jakubiak, H | 1 |
| Turgeon, J | 2 |
| van Noord, C | 1 |
| Aarnoudse, AJ | 1 |
| Eijgelsheim, M | 1 |
| Sturkenboom, MC | 1 |
| Straus, SM | 1 |
| Hofman, A | 1 |
| Kors, JA | 1 |
| Newton-Cheh, C | 1 |
| Witteman, JC | 1 |
| Stricker, BH | 1 |
| Shah, DP | 1 |
| Baez-Escudero, JL | 1 |
| Weisberg, IL | 1 |
| Beshai, JF | 1 |
| Burke, MC | 2 |
| Said, TH | 1 |
| Wilson, LD | 1 |
| Jeyaraj, D | 1 |
| Fossa, AA | 2 |
| Rosenbaum, DS | 1 |
| DePasquale, MJ | 1 |
| Raunig, DL | 1 |
| Avery, MJ | 1 |
| Leishman, DJ | 1 |
| Komiya, N | 1 |
| Tanaka, K | 1 |
| Doi, Y | 1 |
| Fukae, S | 1 |
| Nakao, K | 1 |
| Isomoto, S | 1 |
| Seto, S | 1 |
| Yano, K | 1 |
| Kannankeril, PJ | 1 |
| Roden, DM | 1 |
| Fish, FA | 1 |
| Meyer, T | 1 |
| Boven, KH | 1 |
| Günther, E | 1 |
| Fejtl, M | 1 |
| Aiba, T | 1 |
| Shimizu, W | 3 |
| Inagaki, M | 1 |
| Noda, T | 1 |
| Miyoshi, S | 1 |
| Ding, WG | 1 |
| Zankov, DP | 1 |
| Toyoda, F | 1 |
| Matsuura, H | 1 |
| Sunagawa, K | 1 |
| Milberg, P | 1 |
| Reinsch, N | 1 |
| Osada, N | 1 |
| Wasmer, K | 1 |
| Mönnig, G | 1 |
| Stypmann, J | 1 |
| Breithardt, G | 1 |
| Haverkamp, W | 1 |
| Eckardt, L | 1 |
| Jacobs, A | 1 |
| Knight, BP | 1 |
| McDonald, KT | 1 |
| Zhao, G | 1 |
| Pu, J | 1 |
| Zhang, C | 1 |
| Ma, Y | 1 |
| Li, B | 1 |
| Quan, X | 1 |
| Ohe, T | 3 |
| Kurita, T | 2 |
| Tokuda, T | 1 |
| Shimomura, K | 2 |
| Kawade, M | 2 |
| Arakaki, Y | 1 |
| Aihara, N | 1 |
| Kamakura, S | 1 |
| Kamiya, T | 2 |
| De Ferrari, GM | 1 |
| Nador, F | 1 |
| Beria, G | 1 |
| Sala, S | 1 |
| Lotto, A | 1 |
| Schwartz, PJ | 1 |
| Karch, M | 1 |
| Schmitt, C | 1 |
| Plewan, A | 1 |
| Schmidt, G | 1 |
| Schömig, A | 1 |
| Chouabe, C | 1 |
| Drici, MD | 1 |
| Romey, G | 1 |
| Barhanin, J | 1 |
| Lazdunski, M | 1 |
| Goldschmidt, N | 1 |
| Azaz-Livshits, T | 1 |
| Nir-Paz, R | 1 |
| Ben-Yehuda, A | 1 |
| Muszkat, M | 1 |
| Zhou, JT | 1 |
| Zheng, LR | 1 |
| Liu, WY | 1 |
| Tomita, Y | 1 |
| Fukaya, T | 1 |
| Yamakawa, M | 1 |
| Baba, K | 1 |
| Takao, S | 1 |
| Garson, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Randomized, Placebo-Controlled Single-Dose, Five Period Crossover Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects[NCT01873950] | Phase 1 | 22 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Five Period Crossover Study of the Ability of Late Sodium or Calcium Current Block (Mexiletine, Lidocaine, or Diltiazem) to Balance the Electrocardiographic Effects of hERG Potassium Current Block (Dofetilide or Moxifloxacin)[NCT02308748] | Phase 1 | 22 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Long QT Syndrome-Population Genetics and Cardiac Studies[NCT00005176] | 2,125 participants (Actual) | Observational | 1985-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Different post-dose time-points employ different techniques for altering heart rate (leg raises and postural maneuvers). Using the measurements from all the time-points of postural maneuvers, the QT/RR relationship was modeled as a linear relationship between the square root of RR in seconds and QT in seconds and computed on a by subject, treatment and time-point basis. The change in the QT and heart rate relationship was assessed as the difference (mean and 95% CI) between the slopes from the models for each drug vs. placebo. (NCT01873950)
Timeframe: 24 hours
| Intervention | ratio (Mean) |
|---|---|
| Ranolazine 1500mg | 0.01 |
| Dofetilide 500mcg | 0.06 |
| Verapamil HCl 120 mg | 0.02 |
| Quinidine Sulfate 400mg | 0.11 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | degrees per ng/ml (Mean) |
|---|---|
| Dofetilide 500mcg | -3.9 |
| Verapamil HCl 120 mg | 0.4 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | degrees per mcg/ml (Mean) |
|---|---|
| Ranolazine 1500mg | -1.0 |
| Quinidine Sulfate 400mg | 2.7 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | mV.ns per ng/ml (Mean) |
|---|---|
| Dofetilide 500mcg | 4.0 |
| Verapamil HCl 120 mg | 1.2 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | mV.ns per mcg/ml (Mean) |
|---|---|
| Ranolazine 1500mg | -0.7 |
| Quinidine Sulfate 400mg | 1.6 |
Compute maximum mean placebo, and baseline-adjusted change for: spatial QRS-T angle (degrees) (NCT01873950)
Timeframe: 24 hours
| Intervention | degrees (Least Squares Mean) |
|---|---|
| Ranolazine 1500mg | -2.2 |
| Dofetilide 500mcg | -4.9 |
| Verapamil HCl 120 mg | -2.4 |
| Quinidine Sulfate 400mg | 3.9 |
Compute maximum mean placebo, and baseline-adjusted change for: ventricular gradient (mV*ms). (NCT01873950)
Timeframe: 24 hours
| Intervention | mV*ms (Least Squares Mean) |
|---|---|
| Ranolazine 1500mg | 2.5 |
| Dofetilide 500mcg | 4.8 |
| Verapamil HCl 120 mg | 4.2 |
| Quinidine Sulfate 400mg | 6.0 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | ms per ng/ml (Mean) | ||||
|---|---|---|---|---|---|
| Change in PR | Change in QTc | Change in QRS | Change in J-Tpeakc | Change in Tpeak-Tend | |
| Dofetilide 500mcg | -0.5 | 73.6 | 0.2 | 39.1 | 34.4 |
| Verapamil HCl 120 mg | 28.7 | 3.9 | 0.3 | -0.7 | 3.6 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | ms per mcg/ml (Mean) | ||||
|---|---|---|---|---|---|
| Change in PR | Change in QTc | Change in QRS | Change in J-Tpeakc | Change in Tpeak-Tend | |
| Quinidine Sulfate 400mg | 3.0 | 78.9 | 0.4 | 26.1 | 51.2 |
| Ranolazine 1500mg | 4.2 | 12.0 | 0.8 | 0.7 | 10.0 |
Compute maximum mean placebo, and baseline-adjusted change for: PR (ms), QRS (ms), J-Tpeak (ms), Tpeak-Tend (ms) and QTc (ms) (NCT01873950)
Timeframe: 24 hours
| Intervention | ms (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Change in PR interval | Change in QRS duration | Change in J-Tpeakc | Change in Tpeak-Tend | Change in QTc | |
| Dofetilide 500mcg | 2.3 | 1.1 | 39.5 | 40.0 | 79.3 |
| Quinidine Sulfate 400mg | 5.1 | 2.1 | 29.1 | 49.8 | 78.1 |
| Ranolazine 1500mg | 6.5 | 2.7 | 3.3 | 8.8 | 12.6 |
| Verapamil HCl 120 mg | 32.1 | 2.6 | -2.4 | 4.8 | 5.2 |
Evening dose (moxifloxacin+diltiazem) versus afternoon dose (diltiazem alone). (NCT02308748)
Timeframe: 5 weeks
| Intervention | ms (Mean) |
|---|---|
| Moxifloxacin Alone | 29.9 |
| Moxifloxacin + Diltiazem | 31.3 |
After 3rd dose of mexiletine or lidocaine (evening dose) on treatment day when combined with dofetilide to evening dose on dofetilide alone day. (NCT02308748)
Timeframe: 5 weeks
| Intervention | ms (Mean) | |
|---|---|---|
| Placebo corrected change from baseline in QTc | Placebo corrected change from baseline in J-Tpeakc | |
| Dofetilide + Lidocaine | 18 | 3.5 |
| Dofetilide + Mexiletine | 20.4 | 0.8 |
| Dofetilide Alone | 37.9 | 24.0 |
1 review available for verapamil and Long QT Syndrome
| Article | Year |
|---|---|
Micro-electrode arrays in cardiac safety pharmacology: a novel tool to study QT interval prolongation.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Cation Transport Proteins; Cells, Cultured; El | 2004 |
3 trials available for verapamil and Long QT Syndrome
| Article | Year |
|---|---|
Predicting QRS and PR interval prolongations in humans using nonclinical data.
Topics: Animals; Anti-Arrhythmia Agents; Azabicyclo Compounds; Carbamates; Dogs; Drug Evaluation, Preclinica | 2017 |
Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil.
Topics: Adult; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; ERG1 Potassium Channel; Et | 2015 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
30 other studies available for verapamil and Long QT Syndrome
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go- | 2002 |
Pharmacological characterisation of electrocardiogram J-T
Topics: Animals; DNA-Binding Proteins; Electrocardiography; Flecainide; Guinea Pigs; Long QT Syndrome; Nifed | 2022 |
In Vitro Drug Screening Using iPSC-Derived Cardiomyocytes of a Long QT-Syndrome Patient Carrying KCNQ1 & TRPM4 Dual Mutation: An Experimental Personalized Treatment.
Topics: Arrhythmias, Cardiac; Drug Evaluation, Preclinical; Humans; Induced Pluripotent Stem Cells; KCNQ1 Po | 2022 |
KCNQ1 G219E and TRPM4 T160M polymorphisms are involved in the pathogenesis of long QT syndrome: A case report.
Topics: Adult; Calcium Channel Blockers; Defibrillators, Implantable; Female; Humans; Induced Pluripotent St | 2021 |
Treatment of calmodulinopathy with verapamil.
Topics: Calcium Channel Blockers; Calmodulin; Child, Preschool; Humans; Long QT Syndrome; Male; Ventricular | 2017 |
Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Topics: Action Potentials; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic, Familial; Cell Differentia | 2013 |
Instability of KCNE1-D85N that causes long QT syndrome: stabilization by verapamil.
Topics: Calcium Channel Blockers; Cells, Cultured; Humans; Long QT Syndrome; Polymorphism, Genetic; Potassiu | 2014 |
Halothane-anaesthetized, closed-chest, guinea-pig model for assessment of drug-induced QT-interval prolongation.
Topics: Anesthesia, Inhalation; Anesthetics, Inhalation; Animals; Anti-Arrhythmia Agents; Calcium Channel Bl | 2009 |
Gender-related differences in drug-induced prolongation of cardiac repolarization in prepubertal guinea pigs.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Delayed Rectifier Potassium Channels; Domperidon | 2009 |
Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation.
Topics: Adaptor Proteins, Signal Transducing; Aged; Alleles; Calcium Channel Blockers; Cohort Studies; Femal | 2009 |
Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8).
Topics: Acetanilides; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Autistic Disorder; Drug Therapy, C | 2012 |
Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
Topics: Action Potentials; Animals; Bepridil; Dogs; Dose-Response Relationship, Drug; Electrocardiography; E | 2012 |
The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment.
Topics: Animals; Anti-Arrhythmia Agents; Butylamines; Cisapride; Disease Models, Animal; Dogs; Female; Heart | 2002 |
A patient with LQTS in whom verapamil administration and permanent pacemaker implantation were useful for preventing torsade de pointes.
Topics: Adult; Female; Humans; Long QT Syndrome; Pacemaker, Artificial; Prosthesis Implantation; Torsades de | 2004 |
Suppression of bidirectional ventricular tachycardia and unmasking of prolonged QT interval with verapamil in Andersen's syndrome.
Topics: Adolescent; Anti-Arrhythmia Agents; Diagnosis, Differential; Electrocardiography; Female; Glycogen S | 2004 |
Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cats; Chromans; Heart; | 2005 |
Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3.
Topics: Action Potentials; Animals; Calcium; Electrocardiography; Long QT Syndrome; Male; Rabbits; Torsades | 2005 |
Verapamil decreases ventricular tachyarrhythmias in a patient with Timothy syndrome (LQT8).
Topics: Adrenergic beta-Antagonists; Adult; Calcium Channel Blockers; Combined Modality Therapy; Defibrillat | 2006 |
Modulatory role of verapamil treatment on the cardiac electrophysiological effects of cisapride.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Cells, Cultured; Cisapride; Dose-Response Rela | 2006 |
Effect of calcium-channel antagonist on repolarization heterogeneity of ventricular myocardium in an in vitro rabbit model of long QT syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Female; Heart Ventricl | 2007 |
Epinephrine-induced ventricular premature complexes due to early afterdepolarizations and effects of verapamil and propranolol in a patient with congenital long QT syndrome.
Topics: Action Potentials; Adult; Cardiac Complexes, Premature; Epinephrine; Female; Humans; Long QT Syndrom | 1994 |
Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome.
Topics: Action Potentials; Adolescent; Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Blood Pre | 1995 |
Provocative testing and drug response in a patient with the long QT syndrome.
Topics: Adolescent; Drug Therapy, Combination; Electrocardiography; Epinephrine; Female; Humans; Isoproteren | 1995 |
Effect of calcium channel block on the wall motion abnormality of the idiopathic long QT syndrome.
Topics: Adult; Calcium; Calcium Channels; Echocardiography; Electrocardiography; Female; Humans; Long QT Syn | 1994 |
[Torsade de pointes tachycardia during administration of quinidine and verapamil in atrial fibrillation].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Combinations; Electrocardiography; Fatal Out | 1997 |
HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers.
Topics: Animals; Benzimidazoles; Bepridil; Calcium Channel Blockers; Cloning, Molecular; COS Cells; Heart; I | 1998 |
Compound cardiac toxicity of oral erythromycin and verapamil.
Topics: Aged; Anti-Bacterial Agents; Blood Cell Count; Calcium Channel Blockers; Electrocardiography; Erythr | 2001 |
Role of early afterdepolarization in familial long QTU syndrome and torsade de pointes.
Topics: Action Potentials; Adolescent; Cardiac Pacing, Artificial; Epinephrine; Female; Heart Conduction Sys | 1992 |
[Effective management of the long QT syndrome with verapamil].
Topics: Administration, Oral; Arrhythmias, Cardiac; Child; Female; Humans; Long QT Syndrome; Tachycardia; Ve | 1987 |
Medicolegal problems in the management of cardiac arrhythmias in children.
Topics: Arrhythmias, Cardiac; Child; Child, Preschool; Humans; Infant, Newborn; Long QT Syndrome; Malpractic | 1987 |